Equity Profile

MIRM

Mirum Pharmaceuticals, Inc.

Health CareBiotechnology$5.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, especially after last quarter's significant miss.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare diseases. With a market cap of $6 billion, it operates in the healthcare sector, which is increasingly important as the demand for specialized medical solutions grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, significantly missing expectations. Despite this, the stock rose by 4.04% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Mirum's earnings report, especially after the large EPS miss last quarter. The stock's implied volatility suggests that traders expect a significant price movement.

Bull Case

If Mirum can show improved financials and a path to profitability, it could regain investor confidence and see a strong stock price reaction.

Bear Case

Continued losses and lack of revenue could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS forecast for Q2-2026?

Given the massive EPS miss last quarter, any improvement or further decline will heavily influence investor sentiment.

What revenue growth can we expect moving forward?

Revenue performance is crucial for assessing the company's market position and potential for recovery.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Mirum to stabilize its financials, given recent industry trends toward rare disease treatments.

Supporting Evidence

The options market is pricing a 37.56% move, suggesting significant uncertainty that could lead to overreactions.

Insider selling activity may indicate a lack of confidence in the near-term recovery, which could weigh on stock performance.

Key Risk

If the company reports an EPS improvement, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether Mirum can turn around its financial performance after a significant miss last quarter.

Bull Confirmed If

A reduction in EPS losses to below -$5.00 would indicate a positive trend.

Bear Confirmed If

If EPS remains above -$13.00, it could signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty about the upcoming earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests a stock increase of around +1.33%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.

Miss

Should the company miss again, history indicates a potential decline of around +0.31%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on cost management strategies.
3Insights into market demand for existing treatments.
4Guidance on expected revenue for the next quarter.
5Any changes in competitive landscape or regulatory challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for rare diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, especially after last quarter's significant miss.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, significantly missing expectations. Despite this, the stock rose by 4.04% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of Mirum's earnings report, especially after the large EPS miss last quarter. The stock's implied volatility suggests that traders expect a significant price movement.

Bull Case

If Mirum can show improved financials and a path to profitability, it could regain investor confidence and see a strong stock price reaction.

Bear Case

Continued losses and lack of revenue could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS forecast for Q2-2026?

Given the massive EPS miss last quarter, any improvement or further decline will heavily influence investor sentiment.

What revenue growth can we expect moving forward?

Revenue performance is crucial for assessing the company's market position and potential for recovery.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Mirum to stabilize its financials, given recent industry trends toward rare disease treatments.

Supporting Evidence

The options market is pricing a 37.56% move, suggesting significant uncertainty that could lead to overreactions.

Insider selling activity may indicate a lack of confidence in the near-term recovery, which could weigh on stock performance.

Key Risk

If the company reports an EPS improvement, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether Mirum can turn around its financial performance after a significant miss last quarter.

Bull Confirmed If

A reduction in EPS losses to below -$5.00 would indicate a positive trend.

Bear Confirmed If

If EPS remains above -$13.00, it could signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, reflecting uncertainty about the upcoming earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations, history suggests a stock increase of around +1.33%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.

Miss

Should the company miss again, history indicates a potential decline of around +0.31%, further eroding investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on cost management strategies.
3Insights into market demand for existing treatments.
4Guidance on expected revenue for the next quarter.
5Any changes in competitive landscape or regulatory challenges.